Equities analysts predict that Inovio Pharmaceuticals Inc (NASDAQ:INO) will report earnings of ($0.29) per share for the current quarter, according to Zacks. Two analysts have issued estimates for Inovio Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.24) and the lowest estimate coming in at ($0.33). Inovio Pharmaceuticals reported earnings per share of ($0.36) during the same quarter last year, which would suggest a positive year-over-year growth rate of 19.4%. The company is scheduled to report its next earnings results on Wednesday, March 21st.
According to Zacks, analysts expect that Inovio Pharmaceuticals will report full year earnings of ($1.12) per share for the current financial year, with EPS estimates ranging from ($1.18) to ($1.03). For the next year, analysts expect that the company will post earnings of ($1.26) per share, with EPS estimates ranging from ($1.47) to ($1.04). Zacks’ earnings per share averages are a mean average based on a survey of sell-side analysts that that provide coverage for Inovio Pharmaceuticals.
Inovio Pharmaceuticals (NASDAQ:INO) last released its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.15). Inovio Pharmaceuticals had a negative return on equity of 72.19% and a negative net margin of 221.55%. The company had revenue of $2.60 million during the quarter, compared to analyst estimates of $10.27 million. During the same quarter last year, the business earned ($0.28) earnings per share. The firm’s revenue for the quarter was down 79.2% on a year-over-year basis.
Shares of Inovio Pharmaceuticals (INO) traded down $0.08 on Friday, reaching $5.05. 1,544,549 shares of the company’s stock traded hands, compared to its average volume of 1,650,000. Inovio Pharmaceuticals has a 52 week low of $4.09 and a 52 week high of $9.86. The firm has a market cap of $456.00, a PE ratio of -4.28 and a beta of 2.74.
Hedge funds and other institutional investors have recently bought and sold shares of the business. Bank of Montreal Can boosted its holdings in Inovio Pharmaceuticals by 15.5% in the fourth quarter. Bank of Montreal Can now owns 212,108 shares of the biopharmaceutical company’s stock valued at $876,000 after purchasing an additional 28,400 shares in the last quarter. Belpointe Asset Management LLC acquired a new stake in shares of Inovio Pharmaceuticals during the third quarter worth $150,000. Neuberger Berman Group LLC acquired a new stake in shares of Inovio Pharmaceuticals during the third quarter worth $115,000. Alyeska Investment Group L.P. acquired a new stake in shares of Inovio Pharmaceuticals during the third quarter worth $892,000. Finally, Allianz Asset Management GmbH raised its position in shares of Inovio Pharmaceuticals by 12.4% during the third quarter. Allianz Asset Management GmbH now owns 222,768 shares of the biopharmaceutical company’s stock worth $1,412,000 after purchasing an additional 24,652 shares during the period. 32.11% of the stock is currently owned by institutional investors.
Inovio Pharmaceuticals Company Profile
Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.